

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 3 | 2 | — | — | 5 |
| Hepatitis | D006505 | — | K75.9 | 2 | 2 | 2 | — | — | 5 |
| Chronic hepatitis | D006521 | — | K73.9 | 2 | 2 | 2 | — | — | 5 |
| Hepatitis c | D006526 | — | B19.2 | 1 | 1 | 2 | — | — | 4 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | 1 | 2 | — | — | 4 |
| Polycythemia vera | D011087 | — | D45 | — | — | 1 | — | — | 1 |
| Myeloid leukemia chronic-phase | D015466 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis a | D006506 | EFO_0007305 | B15 | 2 | 2 | — | — | — | 3 |
| Leukemia | D007938 | — | C95 | — | 2 | — | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | — | 2 | — | — | — | 2 |
| Hepatitis b | D006509 | — | — | 1 | 1 | — | — | — | 1 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | 1 | — | — | — | 1 |
| Drug common name | Albinterferon alfa-2b |
| INN | albinterferon alfa-2b |
| Description | Albinterferon (alb-IFN, trade name Albuferon) is a recombinant fusion protein drug consisting of interferon alpha (IFN-α) linked to human albumin. Conjugation to human albumin prolongs the half-life of the IFN-α to about 6 days, allowing to dose it every two to four weeks.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107842 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 4DVS4AG4DF (ChemIDplus, GSRS) |

